- Home
- DBL vs HUMA Comparison
DBL vs HUMA Comparison
Compare DBL & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DBL | HUMA |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 292.0M | 324.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DBL | HUMA |
|---|---|---|
| Price | $15.32 | $1.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $10.13 |
| AVG Volume (30 Days) | 61.0K | ★ 5.0M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 8.67% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,571,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,468.13 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.75 | $1.09 |
| 52 Week High | $15.70 | $6.77 |
Technical Indicators
Market Signals| Indicator | DBL | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 45.43 | 43.40 |
| Support Level | $15.21 | $1.09 |
| Resistance Level | $15.48 | $1.38 |
| Average True Range (ATR) | 0.15 | 0.11 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 42.86 | 54.41 |
Price Performance
Historical ComparisonAbout DBL DoubleLine Opportunistic Credit Fund of Beneficial Interest
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.